搜索筛选:
搜索耗时0.0843秒,为你在为你在102,285,761篇论文里面共找到 4 篇相符的论文内容
发布年度:
Development of Icotinib,An Orally Active Inhibitor of EGFR Tyrosine Kinase with Potential for Cancer
[会议论文] 作者:Yingxiang Wang,Fenlai Tan,Don Zhang,Yunyan Hu,Lieming Ding,
来源:2009年亚太地区肿瘤生物学和医学学术会议暨第四届中国中青年肿瘤专家论坛 年份:2009
...
Development of Icotinib,An Orally Active Inhibitor of EGFR Tyrosine Kinase with Potential for Cancer
[会议论文] 作者:Yingxiang Wang,Fenlai Tan,Don Zhang,Yunyan Hu,Lieming Ding,
来源:2009年亚太地区肿瘤生物学和医学学术会议暨第四届中国中青年肿瘤专家论坛 年份:2009
...
Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advance
[期刊论文] 作者:Yan Song,Jinwan Wang,Xiubao Ren,Jie Jin,Li Mao,Chris Liang,Lieming Ding,Lin Yang,
来源:中国癌症研究(英文版) 年份:2021
Objective: This study evaluated the safety and preliminary efficacy of vorolanib,a novel tyrosine kinase inhibitor,for treatment of patients with advanced solid...
[期刊论文] 作者:汪洋,袁晓玢,熊佳艳,郝志栋,彭星哲,陈琬琳,崔玲玲,李华,王秀兰,何祥波,Min YANG,Congxin LIANG,Yongbin Ma,Lieming DING,Li MAO,,
来源:中国肺癌杂志 年份:2020
肺癌是全世界发病率和致死率最高的恶性肿瘤,其中非小细胞肺癌(non-small cell lung cancer,NSCLC)约占肺癌的85%.间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)重排阳性...
相关搜索: